CrisBio® applications in OneHealth
Prevention of infectious diseases in animals
Up to 75% of new diseases affecting people over the past 10 years originated in animals 13 zoonoses are responsible for 2.2 million deaths per year.
Requiring rapid response and production scale-up.
Universal access to biotech products
Simple production process at significantly lower cost allows commercial viability of biotech product in developing economies.
Most advanced projects
H1N1; H7N9; H5N1
Anti Human rotavirus VP6
Algenex has completed a proof of concept study in avian influenza, a zoonotic disease that has the potential to turn into a global pandemic. In this study, Algenex demonstrated its ability to develop a fully functional and safe vaccine in only four months.
Using CrisBio®, Algenex is ideally positioned to produce and supply large quantities of proteins to pharmaceutical companies developing and manufacturing vaccines quickly and at competitive prices. This would enable widespread immunization, in particular in countries with weak economies and less advanced public health systems.
Algenex has licensed its CrisBio® technology to Biokit (Werfen Group), who is commercializing two diagnostic kits for human applications based on Algenexâ€™ technologies.